ZK91587: A novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus
Abstract
cytosol binding assays have shown the properties of binding of a novel steroid, ZK91587 (15β, 16β-methylene-mexrenone) in the brain of rats. Scatchard and Woolf analyses of the binding data reveal the binding of [3H] ZK91587 to the total hippocampal corticosteroid receptor sites with high affinity (Kd 1.9 nM), and low capacity (Bmax 17.3 fmol/mg protein). When 100-fold excess RU28362 was included simultaneously with [3H] ZK91587, the labelled steroid binds with the same affinity (Kd 1.8 nM) and capacity (Bmax 15.5 fmol/mg protein). Relative binding affinities (RBA) of various steroids for the Type I or Type II corticosteroid receptor in these animals are: Type I: ZK91587 = corticosterone (B) > cortisol (F); Type II: B>K>>>ZK91587. In the binding kinetic study, ZK91587 has a high association rate of binding in the rat (20.0 × 107 M−1 min−). The steroid dissociates following a one slope pattern (), indicating, the present data demonstrate that in the rat hippocampus, ZK91587 binds specifically to the Type I (corticosterone-preferring/ mineralocorticoid-like) receptor.
References (26)
- J.A.M. Van Eekelen et al.
Brain Res.
(1987) - M. Moguilewsky et al.
J. Ster. Biochem.
(1980) - D. Philibert et al.
- G. Scatchard
Ann. N.Y. Acad. SCI.
(1942) - D.D. Keightley et al.
J. Ster. Biochem.
(1983) - E.R. De Kloet et al.
Endocrinology
(1975) - J.W. Funder
Frontiers
- J.H.M.H. Reul et al.
Endocrinology
(1985) - W. Sutanto et al.
Endocrinology
(1987) - J.W. Funder et al.
Ann. Rev. Physiol.
(1987)
Endoc. Rev.
Science
Endocrinology
Cited by (22)
Glucocorticoid receptors in lateral septum are involved in the modulation of the emotional sequelae induced by social defeat
2006, Behavioural Brain ResearchThe current research studied the behavior adopted in the elevated plus maze (EPM) of rats previously subjected to a social defeat using the resident-intruder paradigm. One day after defeat, intruder animals exhibited an anxiogenic-like behavior in the EPM.
In addition, we also evaluated the role of the corticosteroid receptor system (minerlocorticoid – MR – and glucocorticoid – GR – receptors) from the lateral septum (LS) on the anxiety generated by social defeat. The LS is an area of the aversive circuitry that is preferentially activated in passive defensive postures, and participates – together with other brain areas – in the modulation of aversive states. Intruder animals were infused into the LS with the MR or GR antagonist (ZK 91587 and RU 38486, respectively) and then submitted to social stress. All rats were tested in the EPM 1 day later. Only the administration of the GR antagonist, but not the MR antagonist, into the LS normalized the anxiogenic response induced by defeat.
Furthermore, we examined whether a single injection of corticosterone (CS) could induce the same influence on the behavior in the EPM as that observed after social defeat. Moreover, we explored the effect of local infusions of MR or GR antagonists into the LS on the behavior exhibited by CS-treated rats in a subsequent EPM exposure. CS administration also exerted an increased anxiogenic-like behavior, which was normalized only by the local infusion of the GR antagonist.
Based on these findings, we suggest that CS secreted by emotionally relevant stimuli acting via GR in LS plays an important role in the modulation of the emotional sequelae induced by social defeat.
Downregulation of brain mineralocorticoid and glucocorticoid receptor by antisense oligodeoxynucleotide treatment fails to alter spatial navigation in rats
1998, European Journal of PharmacologyAdult male Brown Norway rats were long-term intracerebroventricularly (i.c.v.) infused with antisense oligodeoxynucleotides (18-mer, double endcapped phosphorothioate protected) targeting either mineralocorticoid or glucocorticoid receptor mRNA, or received the respective mixed bases sequence or vehicle. Mineralocorticoid receptor-mixed bases and glucocorticoid receptor-mixed bases oligodeoxynucleotide infusion (1 μg/0.5 μl/h) over a time period of seven days did not alter hippocampal mineralocorticoid receptor and glucocorticoid receptor binding when compared to vehicle treatment. In contrast, i.c.v. administration of mineralocorticoid receptor, as well as glucocorticoid receptor-antisense over the same time period resulted in a significantly reduced binding of mineralocorticoid receptor and glucocorticoid receptor in the hippocampus [mineralocorticoid receptor-antisense group approx. 72% of mineralocorticoid receptor-mixed bases and vehicle groups (100%); glucocorticoid receptor antisense group approx. 77% of glucocorticoid receptor-mixed bases and vehicle]. The specificity of these antisense effects is indicated by the finding that rats treated with mineralocorticoid receptor-antisense did not show any changes in glucocorticoid receptor and vice versa. Animals treated according to this infusion protocol and tested in the Morris water maze for their spatial navigation abilities failed to show significant differences among the groups. These data indicate that a reduction of hippocampal mineralocorticoid receptor or glucocorticoid receptor binding capacity by 20–30% does not interfere with spatial navigation.
Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: Receptor measures and functional studies
1998, Journal of Steroid Biochemistry and Molecular BiologyCorticosterone regulates a wide range of physiological parameters. Two receptors for corticosterone have been identified, the mineralocorticoid (type I) receptor (MR) and the glucocorticoid (type II) receptor (GR). To determine the relative role of these two receptors in mediating the effects of endogenous corticosterone, many studies have relied on the use of putative selective corticosteroid receptor antagonists. This study further examined the in vivo receptor selectivity of two compounds, RU28318 and RU40555 that are believed to be selective antagonists for MR and GR, respectively. Acute treatment of adrenalectomized rats with RU28318 (10–50 mg/kg) selectively decreased ex-vivo available MR binding in the hippocampus, whereas acute treatment with RU40555 (10–30 mg/kg) selectively decreased available GR binding in the hippocampus and pituitary. These receptor binding measures suggest that RU28318 in vivo selectively occupied MR, and that RU40555 in vivo selectively occupied GR. In functional studies, RU28318 (50 mg/kg) blocked the normalizing effect of aldosterone (120 μg/kg) on saline intake of adrenalectomized rats. RU40555 (30 mg/kg) blocked the suppressive effect of dexamethasone (50 μg/kg) on acute stress-induced corticosterone secretion. These studies further support the in vivo corticosteroid receptor selectivity of these two compounds and confirms their effective corticosteroid antagonistic properties.
Sex differences in corticosteroid binding in the rat brain: An in vitro autoradiographic study
1996, Brain ResearchSeveral previous studies have raised the possibility of sex differences in the distribution of corticosteroid receptors in the brain. The direction and magnitude of these differences have, however, remained controversial. In the present study, we have re-examined the concentrations of mineralocorticoid (MR) and glucocorticoid (GR) receptors in the brains of male and female rats at varying times (1 to 6 days) after combined gonadectomy (GDX) and adrenalectomy (ADX). Cytosol binding assays confirmed the presence of higher MR levels in short-term (3-day) GDX-ADX males. This difference disappeared by 6 days after surgery, as receptor levels in females rose to be equivalent to those in males. Using an improved in vitro autoradiographic method, the distribution of MR and GR was studied in males and females 3 days after GDX-ADX. The distribution of MR and GR in the brains of these rats was similar in the two sexes. MR binding in the male, however, was significantly greater than that in the female throughout the principal cell fields of the hippocampus. Measurements of circulating corticosterone levels at the time of GDX-ADX suggest that this sex difference may reflect a more rapid recovery of the MR system in males than in females following the stress-induced rise in corticosterone secretion occurring at the time of surgery.
Activation of protein kinase A potentiates the transcriptional response mediated by the glucocorticoid receptor in responsive fibroblasts and in mammary carcinoma cells. This potentiation is ligand-dependent and occurs without detectable change in the phosphorylation of receptor. The transcriptional response to glucocorticoid or progestin agonists can be blocked by potent antagonists like RU 486. However, upon activation of protein kinase A, the antagonist action of RU 486 on both receptors is blunted. Indeed, RU 486 can itself activate transcription of a hormone-responsive promoter. The conditional agonist activity is observed with type II antagonists, those which recapitulate many of the early steps of ligand-dependent receptor activation, but not type I antagonists, which do not. These studies have now been extended to antimineralocorticoids. In COS-1 cells transfected with a mineralocorticoid receptor expression vector, treatment with 8-BromocAMP potentiates the response to the agonist aldosterone and elicits additional agonist activity in mineralocorticoid antagonists. A model is proposed wherein type II antagonist-receptor complexes occupy receptor binding sites on the genome. The antagonist, however, fails to promote a receptor conformation that can interact productively with a coactivator mediating the communication between receptor and the basal transcription apparatus. Activation of protein kinase A results in the recruitment or activation of a coactivator that permits recovery of receptor-mediated activation function. The recent documentation of conditional agonist activity in antagonists of several different classes of steroids could have significant implications for the use of steroid antagonists in the clinical setting, representing a previously unrecognized mechanism for the development of steroid resistance.
Corticosterone is a preferable ligand for measuring rat brain corticosteroid receptors: competition by RU 28362 and RU 26752 for dexamethasone binding in rat hippocampal cytosol
1993, Brain ResearchIt is unclear whether in vitro corticosteroid receptor binding assays have used inappropriately high concentrations of synthetic corticosteroid competitors, thereby potentially introducing error into estimates of type I (mineralocorticoid) and type II (glucocorticoid) receptor binding. To determine more accurately the concentration of blockers necessary to discriminate between these two sites, we have derivedKi values for the competition of dexamethasone, RU 28362 and RU 26752 for [3H]corticosterone and [3H]dexamethasone binding in rat hippocampus. Non-specific binding of both radioligands was defined with unlabeled dexamethasone to exclude transcortin. The type II agonist RU 28362 competed for only a portion of [3H]corticosterone binding, exhibiting aKi of 0.5 nM for this binding. In contrast, RU 28362 fully competed all binding of a saturating concentration of [3H]dexamethasone, even though [3H]dexamethasone also recognized type I receptors, defined as specific [3H]corticosterone binding in the presence of 80 nM RU 28362. RU 28362 competition for [3H]dexamethasone binding exhibited characteristics of a 2-site interaction, withKis of 0.3 and 194 nM. The type I receptor antagonist RU 26752 competed less effectively for [3H]corticosterone and [3H]dexamethasone binding, but nonetheless competed fully within a 1000-fold concentration range. Even at a level less than 125 × itsKi for type I binding, RU 26752 still inhibited virtually all type II receptor binding by [3H]corticosterone. We conclude that type I and II receptors in rat brain are best distinguished using [3H]corticosterone as the labelling ligand, with cold RU 28362 and dexamethasone to eliminate binding to type II and transcortin sites, respectively. RU 26752 discriminates poorly between rat brain type I and type II receptors, at least in vitro, while the competition of RU 28362 for all [3H]dexamethasone binding suggests that, without careful adjustment of RU 28362 concentrations, this latter combination of ligands may underestimate type I receptor levels.